Incannex says Phase 2 RePOSA trial shows IHL-42X reduces sleep apnea severity

• Incannex won MedTech Breakthrough’s “Best New Technology Solution for Drug Development” award for IHL-42X, its oral fixed-dose combination therapy in development for obstructive sleep apnea.
• Phase 2 RePOSA trial results were already presented, showing clinically meaningful improvements in sleep apnea severity, oxygenation, sleep quality, patient-reported fatigue.
• Recognition supports company’s push toward late-stage development, positioning IHL-42X as a potential alternative to existing standards of care in a large unmet-need market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-054725), on May 12, 2026, and is solely responsible for the information contained therein.